Back to search

Article

The impact of pretransplant use of tyrosine kinase inhibitors on allogeneic stem cell transplantation in patients with chronic myeloid leukemia - A single-institution retrospective study

2022-09-22

Abstract excerpt

<title>Abstract</title> <p>Second- and third-generation (2/3G) tyrosine kinase inhibitors (TKIs) possess excellent treatment effects on chronic myeloid leukemia (CML), and at least one 2/3G TKI is mostly incorporated into the first treatment of CML in all phases. However, the impact of 2/3G TKIs on subsequent allogeneic stem cell transplantation (allo-SCT) remains to be elucidated. We retrospectively evaluated ho...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work
60fb8d37-4b04-5225-b0eb-0fbf49cc2105
DOI
10.21203/rs.3.rs-2050971/v1
Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest
Interactive article relationship graphSelect a related publication card to move it into the centre and load its closest explainable connections. Solid lines are source-backed structured connections. Dashed lines are semantic discovery signals and are not scientific evidence.
The impact of pretransplant use of tyrosine kinase inhibitors on allogeneic stem cell transplantation in patients with chronic myeloid leukemia - A single-institution retrospective studyDOI 10.21203/rs.3.rs-2050971/v1
Impact of First- and Second-Generation Tyrosine Kinase Inhibitors on the Development of Graft-Versus-Host Disease in Individuals with Chronic Myeloid Leukemia: A Retrospective Analysis on behalf of the Polish Adult Leukaemia GroupSemantic proximity
Chronic myelogenous leukemia: role of stem cell transplant in the imatinib era.Semantic proximity
Comparative Effectiveness of Newer Tyrosine Kinase Inhibitors Versus Imatinib in the First-Line Treatment of Chronic-Phase Chronic Myeloid Leukemia Across Risk Groups: A Systematic Review and Meta-Analysis of Eight Randomized Trials.Semantic proximity
Long-term outcome of Tyrosine Kinase Inhibitor treatment in children and adolescents with newly diagnosed chronic myeloid leukemia in chronic phase: A single-center experience in ChinaSemantic proximity
Best First Line Tyrosine Kinase Inhibitor for Chronic Phase Chronic Myeloid Leukemia in Adults: A Network Meta-AnalysisSemantic proximity
Therapy of Chronic Myeloid Leukemia: Twilight of the Imatinib Era?Semantic proximity
Pretransplant administration of imatinib for allo-HSCT in patients with BCR-ABL–positive acute lymphoblastic leukemiaSemantic proximity
Safety and Efficacy of TKIs in Very Elderly Patients (≥75 Years) with Chronic Myeloid LeukemiaSemantic proximity
TKI Maintenance After Stem-Cell Transplantation for FLT3-ITD Positive Acute Myeloid Leukemia: A Systematic Review and Meta-Analysis.Semantic proximity
When to Consider Allogeneic Transplantation in CML.Semantic proximity
Update on the use of hydroxyurea for the early management of chronic-phase- chronic myeloid leukemia: data from a real-world cohortSemantic proximity
CML in the Very Elderly: The Impact of Comorbidities and TKI Selection in a Real-life Multicenter StudySemantic proximity
Select a neighboring publication to make it the new centre.